METASTATIC CELLS DETECTION IN LUNGS USING HP HE AND TARGETED CONTRAST AGENT

使用 HP HE 和靶向造影剂检测肺部转移细胞

• 批准号: 8363170
• 负责人: Rosa Tamara Branca
• 金额: $ 1.23万
• 依托单位: DUKE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-07-01 至 2012-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8363170
• 关键词: Achievement; American Cancer Society; Breast; Bronchoscopy; Cancer Detection; Cells; Choriocarcinoma; Clinical; Colorectal; Common Neoplasm; Contrast Media; Data; Detection; Development; Diagnosis; Disease; Disseminated Malignant Neoplasm; Drainage procedure; Fine needle aspiration biopsy; Funding; Grant; Head and neck structure; Helium; Image; Injection of therapeutic agent; Investigation; Kidney; Lung; Magnetic Resonance Imaging; Malignant Neoplasms; Malignant neoplasm of lung; Mammary Neoplasms; Metastatic Neoplasm to the Lung; Methods; Micrometastasis; Microscopy; Modality; Monitor; Mus; National Center for Research Resources; PET/CT scan; Patients; Pilot Projects; Positron-Emission Tomography; Primary Neoplasm; Principal Investigator; Prostate; Publications; Renal carcinoma; Research; Research Infrastructure; Resources; Scanning; Screening procedure; Sensitivity and Specificity; Source; Sputum Cytology Screening; Techniques; Testicular Teratoma; Thyroid carcinoma; Time; United States National Institutes of Health; Venous; cancer cell; cost; interest; melanoma; mortality; neoplastic cell; osteosarcoma; tumor

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. We developed a new method that uses Hyperpolarized Helium MRI and targeted contrast agent to detect metastatic cancer cells in lungs. We aim to establish the sensitivity and specificity of our method with respect to other clinically available techniques, such as PET and CT scan. We plan on scanning breast tumor bearing mice after they received an injection of our contrast agent LHRH-SPION. We will utilize 10 breast tumor mice that have already been imaged with other modalities (CT and PET) and have shown sign of metastatic cancer cells in lungs. We are requesting 5 days of additional MRI time to complete our pilot project of the title above. With this time we expect to generate the necessary data for a high-profile publication, as well as preliminary data for an R01 application. Below are additional details about the project achievements thus far. According to the American Cancer Society, more than 1.44 million people will be diagnosed with cancer, and more than 560 thousand will die of it this year in the US. The high mortality rate in these patients has been attributed to the development of subclinical occult micrometastasis simultaneously with the more easily diagnosed primary tumor. Thus, the search for these micrometastatic cells is an issue of significant clinical interest. Sensitive non-invasive methods are needed both for early metastatic disease detection and to monitor subsequent treatments. We are focusing our investigation on the MRI detection of specifically targeted pulmonary metastases. Pulmonary metastases are common and most frequently occur with tumors that have rich systemic venous drainage, like renal cancers, bone sarcomas, choriocarcinomas, melanomas, testicular teratomas, and thyroid carcinomas. However most pulmonary metastases arise from common tumors, such as breast, colorectal, prostate, bronchial, head-and-neck, and renal and, of course, lung cancers. Pulmonary metastases are present in 20-54% of all patients who die of cancer, and detection of pulmonary metastases is crucial in the treatment of patients with cancer. Current screening techniques in lungs (fine-needle aspiration (FNA), bronchoscopy, sputum cytology, PET, and CT are invasive and/or lack the sensitivity necessary to detect micrometastases, single disseminated cells, or small tumor cell clusters in lungs.

该副本是利用资源的众多研究子项目之一 由NIH/NCRR资助的中心赠款提供。对该子弹的主要支持 而且，副投影的主要研究员可能是其他来源提供的 包括其他NIH来源。 列出的总费用可能 代表subproject使用的中心基础架构的估计量， NCRR赠款不直接向子弹或副本人员提供的直接资金。 我们开发了一种使用超极化氦气MRI和靶向对比剂来检测肺中转移性癌细胞的新方法。我们旨在建立我们方法在其他临床上可用技术（例如PET和CT扫描）方面的敏感性和特异性。我们计划在注射我们的对比剂LHRH-Spion后扫描乳腺肿瘤小鼠。我们将利用已经与其他方式成像（CT和PET）成像的10只乳腺肿瘤小鼠，并显示了肺中转移性癌细胞的迹象。我们要求5天的额外MRI时间来完成上述标题的试点项目。在这个时候，我们期望为备受瞩目的出版物生成必要的数据，以及R01应用程序的初步数据。以下是迄今为止有关项目成就的其他详细信息。 根据美国癌症协会的数据，将有超过144万人被诊断出患有癌症，今年在美国将死于5.6万人。这些患者的高死亡率归因于同时与更容易诊断的原发性肿瘤同时发育。因此，对这些微转移细胞的搜索是临床意义重大的问题。早期转移性疾病检测和监测随后的治疗需要敏感的非侵入性方法。 我们将研究集中在特定靶向肺转移的MRI检测上。肺转移是常见的，并且最常发生在具有丰富的全身静脉排水的肿瘤中，例如肾脏癌，骨肉瘤，绒毛膜脊髓瘤，黑色素瘤，睾丸畸胎瘤和甲状腺癌。然而，大多数肺转移都来自常见肿瘤，例如乳腺癌，结直肠骨，前列腺，支气管，头颈，肾脏，当然还有肺癌。在所有死于癌症的患者中，有20-54％的肺转移存在，肺转移的检测对于癌症患者的治疗至关重要。当前的肺部筛查技术（细针吸入（FNA），支气管镜检查，痰细胞学，PET和CT是侵入性的，并且/或缺乏检测肺中检测微量转移酶，单个传播细胞或小型肿瘤细胞簇所必需的灵敏度。